Research

I am currently Chairman of the International Breast Cancer Intervention Study (IBIS) Steering Group and the ATAC trial. I have worked extensively in breast cancer and was the first to report the effect of tamoxifen on contralateral tumours as an indicator of its potential chemopreventive role. I demonstrated that a change in mammographic breast density on endocrine treatment is a biomarker for its effectiveness.

I am involved in studies on the use of HPV assays for cervical screening, the use of flexible sigmoidoscopy for colorectal cancer screening and markers for the behaviour of early prostate cancer.

I am the statistician for several major breast cancer trials and maintain an active interest in developing new statistical methodology, especially in the area of adjustments for non-compliance and cross-over, and multi-arm clinical trials.

Other Activities

• Fellow of the Academy of Medical Sciences
• Fellow of the Royal Society
• Science Strategy Committee member for Breast Cancer Now
• Research Strategy Group member for Prostate Cancer UK

Major Funding

• 2018-2023- CRUK, Catalyst
• 2017-2020- Barts Charity, Preventative Neurology
• 2014-2019- CRUK, Cancer Prevention
• 2007-2019- CRUK, IBIS II

Recent Publications

The importance of long-term follow up of participants in clinical trials. Cuzick J Br J Cancer (2022) (2)
https://www.ncbi.nlm.nih.gov/pubmed/36456713

Interpreting the results of noninferiority trials—a review Cuzick J, Sasieni P British Journal of Cancer (2022) 127(7) 1755-1759

DNA methylation testing with S5 for triage of high-risk HPV positive women Adcock R, Nedjai B, Lorincz AT et al. International Journal of Cancer (2022) 151(7) 993-1004

Validation of the cell cycle progression score to differentiate indolent from aggressive prostate cancer in men diagnosed through transurethral resection of the prostate biopsy Cuzick JM, Stone S, Lenz L et al. Cancer Reports (2022) 5(7)

Breast cancer risk stratification in women of screening age: Incremental effects of adding mammographic density, polygenic risk, and a gene panel Evans DGR, van Veen EM, Harkness EF et al. Genetics in Medicine (2022) 24(7) 1485-1494

Adherence to National Guidelines on Cervical Screening: A Population-Based Evaluation From a Statewide Registry Castle PE, Kinney WK, Chen L et al. Journal of the National Cancer Institute (2022) 114(7) 626-630

Assessment of Risk Factors and Early Presentations of Parkinson Disease in Primary Care in a Diverse UK Population Simonet C, Bestwick J, Jitlal M et al. JAMA Neurology (2022) 79(7) 359-369

The Lancet Breast Cancer Commission: tackling a global health, gender, and equity challenge Coles CE, Anderson BO, Cameron D et al. The Lancet (2022) 399(7) 1101-1103

Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials Bradley R, Braybrooke J, Gray R et al. The Lancet Oncology (2022) 23(7) 382-392

Comparison of StemPrintER with Oncotype DX Recurrence Score for predicting risk of breast cancer distant recurrence after endocrine therapy Pece S, Sestak I, Montani F et al. European Journal of Cancer (2022) 164(7) 52-61

Biography

I received my BSc in Mathematics and Physics from Harvey Mudd College, Claremont, California. I then studied an MSc in Mathematics at the University of London. I obtained my PhD in Mathematics from Claremont Graduate School, Claremont, California.

I was appointed John Snow Professor of Epidemiology at Queen Mary University of London. In 2017, I was awarded a CRUK Lifetime Achievement Award and a CBE.